Back to Newsroom

StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord Injury

NEWARK, Calif., Oct. 2, 2013 — StemCells, Inc. (Nasdaq:STEM) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application for clinical testing of the Company’s proprietary HuCNS-SC human neural stem cells as a treatment for spinal cord injury.